Clinical Trial: Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

U.S., July 9 -- ClinicalTrials.gov registry received information related to the study (NCT07689292) titled 'Sac-TMT Combined With Fruquintinib as Second-Line Treatment in Patients With Advanced Gastric/Gastroesophageal Junction Adenocarcinoma' on June 30.

Brief Summary: This is a phase 2 multicenter study that will evaluate the safety and efficacy of sacituzumab tirumotecan (Sac-TMT) plus fruquintinib for the treatment of participants with locally advanced or metastatic gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma who have failed 1 prior line of therapy.

Study Start Date: July 31

Study Type: INTERVENTIONAL

Condition: Gastric Adenocarcinoma Gastroesophageal Junction (GEJ) Adenocarcinoma Gastro-esophageal Junction Adenoc...